SU1017170A3 - Способ получени производных 3-амино-1-бензоксепина или их стереоизомеров, или их солей - Google Patents
Способ получени производных 3-амино-1-бензоксепина или их стереоизомеров, или их солей Download PDFInfo
- Publication number
- SU1017170A3 SU1017170A3 SU802953852A SU2953852A SU1017170A3 SU 1017170 A3 SU1017170 A3 SU 1017170A3 SU 802953852 A SU802953852 A SU 802953852A SU 2953852 A SU2953852 A SU 2953852A SU 1017170 A3 SU1017170 A3 SU 1017170A3
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- hydrogen
- alkyl
- tetrahydro
- rac
- formula
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 22
- LIYVVGRAWVYPBS-UHFFFAOYSA-N 1-benzoxepin-3-amine Chemical class C1=CC(N)=COC2=CC=CC=C21 LIYVVGRAWVYPBS-UHFFFAOYSA-N 0.000 title abstract description 5
- 238000004519 manufacturing process Methods 0.000 title description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 37
- 239000001257 hydrogen Substances 0.000 claims abstract description 37
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 20
- 150000002431 hydrogen Chemical class 0.000 claims abstract description 11
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims abstract description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 7
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims abstract description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 5
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 5
- 239000001301 oxygen Substances 0.000 claims abstract description 5
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 3
- 150000002367 halogens Chemical class 0.000 claims abstract description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 3
- 125000001424 substituent group Chemical group 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 30
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 21
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 19
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 17
- -1 or as stereoisomers Chemical class 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 claims description 12
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 10
- 229910052759 nickel Inorganic materials 0.000 claims description 8
- 230000002378 acidificating effect Effects 0.000 claims description 7
- 230000007935 neutral effect Effects 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- 239000012279 sodium borohydride Substances 0.000 claims description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 4
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 3
- 239000012448 Lithium borohydride Substances 0.000 claims description 3
- 239000000010 aprotic solvent Substances 0.000 claims description 3
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims description 3
- 229910052744 lithium Inorganic materials 0.000 claims description 3
- 239000012280 lithium aluminium hydride Substances 0.000 claims description 3
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 2
- 230000009471 action Effects 0.000 claims description 2
- 239000003586 protic polar solvent Substances 0.000 claims description 2
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 2
- 239000007868 Raney catalyst Substances 0.000 claims 1
- 229910000564 Raney nickel Inorganic materials 0.000 claims 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims 1
- MOOAHMCRPCTRLV-UHFFFAOYSA-N boron sodium Chemical compound [B].[Na] MOOAHMCRPCTRLV-UHFFFAOYSA-N 0.000 claims 1
- 230000003197 catalytic effect Effects 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 59
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 58
- 241000700159 Rattus Species 0.000 description 34
- 239000000243 solution Substances 0.000 description 33
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 26
- 210000002784 stomach Anatomy 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 10
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 10
- 235000019441 ethanol Nutrition 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 229910052938 sodium sulfate Inorganic materials 0.000 description 7
- 235000011152 sodium sulphate Nutrition 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 229940088623 biologically active substance Drugs 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000005984 hydrogenation reaction Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000001640 fractional crystallisation Methods 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- MYBHWOOKDVJOQH-UHFFFAOYSA-N N-methyl-1-benzoxepin-3-amine Chemical compound CNC1=COC2=C(C=C1)C=CC=C2 MYBHWOOKDVJOQH-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 2
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- KLBCQBRUFJODSQ-UHFFFAOYSA-N 1-benzoxepin-5-ol Chemical compound OC1=CC=COC2=CC=CC=C12 KLBCQBRUFJODSQ-UHFFFAOYSA-N 0.000 description 1
- PDBWWVFLJFATMD-UHFFFAOYSA-N 2-ethyl-2h-chromene Chemical compound C1=CC=C2C=CC(CC)OC2=C1 PDBWWVFLJFATMD-UHFFFAOYSA-N 0.000 description 1
- CTHZQSCBKROLEN-UHFFFAOYSA-N 2-ethyl-3,4-dihydro-2h-chromene Chemical compound C1=CC=C2OC(CC)CCC2=C1 CTHZQSCBKROLEN-UHFFFAOYSA-N 0.000 description 1
- BPQVCZBLBPZORI-UHFFFAOYSA-N 3-(methylamino)-3,4-dihydro-2h-1-benzoxepin-5-one Chemical compound O=C1CC(NC)COC2=CC=CC=C21 BPQVCZBLBPZORI-UHFFFAOYSA-N 0.000 description 1
- FRPHFZCDPYBUAU-UHFFFAOYSA-N Bromocresolgreen Chemical compound CC1=C(Br)C(O)=C(Br)C=C1C1(C=2C(=C(Br)C(O)=C(Br)C=2)C)C2=CC=CC=C2S(=O)(=O)O1 FRPHFZCDPYBUAU-UHFFFAOYSA-N 0.000 description 1
- 101100139845 Caenorhabditis elegans rac-2 gene Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000011785 NMRI mouse Methods 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000031463 Palmoplantar Diffuse Keratoderma Diseases 0.000 description 1
- 201000000660 Pyloric Stenosis Diseases 0.000 description 1
- 101100453673 Rattus norvegicus Kdm3a gene Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910010277 boron hydride Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 201000006079 nonepidermolytic palmoplantar keratoderma Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- ZJMLWSBTWUELPE-UHFFFAOYSA-N oxo(phenyl)methanesulfonic acid Chemical compound OS(=O)(=O)C(=O)C1=CC=CC=C1 ZJMLWSBTWUELPE-UHFFFAOYSA-N 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D313/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19792931399 DE2931399A1 (de) | 1979-08-02 | 1979-08-02 | Neue 3-amino-1-benzoxepin-derivate und ihre salze, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU1017170A3 true SU1017170A3 (ru) | 1983-05-07 |
Family
ID=6077478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU802953852A SU1017170A3 (ru) | 1979-08-02 | 1980-08-01 | Способ получени производных 3-амино-1-бензоксепина или их стереоизомеров, или их солей |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US4279904A (OSRAM) |
| EP (1) | EP0024560B1 (OSRAM) |
| JP (1) | JPS5649374A (OSRAM) |
| AT (1) | ATE3038T1 (OSRAM) |
| AU (1) | AU532394B2 (OSRAM) |
| CA (1) | CA1161857A (OSRAM) |
| DD (1) | DD154018A5 (OSRAM) |
| DE (2) | DE2931399A1 (OSRAM) |
| DK (1) | DK152044C (OSRAM) |
| ES (1) | ES8104269A1 (OSRAM) |
| FI (1) | FI802384A7 (OSRAM) |
| GR (1) | GR69358B (OSRAM) |
| HU (1) | HU181736B (OSRAM) |
| IE (1) | IE50100B1 (OSRAM) |
| IL (1) | IL60552A (OSRAM) |
| NO (1) | NO155135C (OSRAM) |
| NZ (1) | NZ194329A (OSRAM) |
| PH (1) | PH15870A (OSRAM) |
| PT (1) | PT71600A (OSRAM) |
| SU (1) | SU1017170A3 (OSRAM) |
| ZA (1) | ZA804548B (OSRAM) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2405777C1 (ru) * | 2009-05-13 | 2010-12-10 | Государственное образовательное учреждение высшего профессионального образования "Пермский государственный университет" | СПОСОБ ПОЛУЧЕНИЯ 4-БЕНЗОИЛ-1Н-БЕНЗО[c]ОКСЕПИН-3-ОНА |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4556656A (en) * | 1978-10-23 | 1985-12-03 | The Upjohn Company | 2-Benzoxepins |
| DE3440296A1 (de) * | 1984-11-05 | 1986-05-15 | Kali-Chemie Pharma Gmbh, 3000 Hannover | 3-amino-2,3-dihydro-1-benzoxepin-verbindungen sowie verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| DE3440295A1 (de) * | 1984-11-05 | 1986-05-15 | Kali-Chemie Pharma Gmbh, 3000 Hannover | Verfahren zur diastereoselektiven reduktion von 3-amino-1-benzoxepin-5(2h)-onen |
| AU597671B2 (en) * | 1986-06-20 | 1990-06-07 | Suntory Limited | 2-Phenylbenzoxepin derivative |
| JP2931986B2 (ja) * | 1989-02-17 | 1999-08-09 | 武田薬品工業株式会社 | アラルキルアミン誘導体 |
| CN103554077B (zh) * | 2013-10-29 | 2014-12-17 | 云南烟草科学研究院 | 一种色酮类化合物及其制备方法和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1593760A1 (de) * | 1967-02-01 | 1972-06-08 | Boehringer Sohn Ingelheim | Verfahren zur Herstellung neuer Benz-epinderivate |
| US3991082A (en) * | 1975-03-03 | 1976-11-09 | Warner-Lambert Company | 4-Substituted-2,3-dihydro-1-benzoxepin-3,5-diones and tautomers |
| US4153612A (en) * | 1977-10-31 | 1979-05-08 | The Upjohn Company | 2-Benzoxepins |
-
1979
- 1979-08-02 DE DE19792931399 patent/DE2931399A1/de not_active Withdrawn
-
1980
- 1980-07-03 IE IE1386/80A patent/IE50100B1/en unknown
- 1980-07-11 IL IL60552A patent/IL60552A/xx unknown
- 1980-07-11 NZ NZ194329A patent/NZ194329A/xx unknown
- 1980-07-14 AU AU60390/80A patent/AU532394B2/en not_active Ceased
- 1980-07-16 PH PH24296A patent/PH15870A/en unknown
- 1980-07-24 PT PT71600A patent/PT71600A/pt unknown
- 1980-07-28 ZA ZA00804548A patent/ZA804548B/xx unknown
- 1980-07-28 US US06/173,075 patent/US4279904A/en not_active Expired - Lifetime
- 1980-07-29 AT AT80104467T patent/ATE3038T1/de not_active IP Right Cessation
- 1980-07-29 HU HU801889A patent/HU181736B/hu unknown
- 1980-07-29 EP EP80104467A patent/EP0024560B1/de not_active Expired
- 1980-07-29 DE DE8080104467T patent/DE3062741D1/de not_active Expired
- 1980-07-30 FI FI802384A patent/FI802384A7/fi not_active Application Discontinuation
- 1980-07-31 GR GR62576A patent/GR69358B/el unknown
- 1980-08-01 JP JP10515880A patent/JPS5649374A/ja active Granted
- 1980-08-01 DD DD80223066A patent/DD154018A5/de unknown
- 1980-08-01 SU SU802953852A patent/SU1017170A3/ru active
- 1980-08-01 ES ES493926A patent/ES8104269A1/es not_active Expired
- 1980-08-01 CA CA000357545A patent/CA1161857A/en not_active Expired
- 1980-08-01 DK DK333380A patent/DK152044C/da not_active IP Right Cessation
- 1980-08-01 NO NO802325A patent/NO155135C/no unknown
Non-Patent Citations (1)
| Title |
|---|
| 1.Эльдерфильд Р. Гетероциклич ские соединени . Т.2, Mi, ИЛ, 1954, с, 195, * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2405777C1 (ru) * | 2009-05-13 | 2010-12-10 | Государственное образовательное учреждение высшего профессионального образования "Пермский государственный университет" | СПОСОБ ПОЛУЧЕНИЯ 4-БЕНЗОИЛ-1Н-БЕНЗО[c]ОКСЕПИН-3-ОНА |
Also Published As
| Publication number | Publication date |
|---|---|
| IL60552A0 (en) | 1980-09-16 |
| CA1161857A (en) | 1984-02-07 |
| NO155135B (no) | 1986-11-10 |
| PT71600A (en) | 1980-08-01 |
| DK333380A (da) | 1981-02-03 |
| JPS5649374A (en) | 1981-05-02 |
| NO802325L (no) | 1981-02-03 |
| IE50100B1 (en) | 1986-02-19 |
| AU532394B2 (en) | 1983-09-29 |
| JPS6360750B2 (OSRAM) | 1988-11-25 |
| DE2931399A1 (de) | 1981-02-26 |
| DK152044B (da) | 1988-01-25 |
| DD154018A5 (de) | 1982-02-17 |
| NO155135C (no) | 1987-02-18 |
| ZA804548B (en) | 1981-07-29 |
| GR69358B (OSRAM) | 1982-05-20 |
| PH15870A (en) | 1983-04-13 |
| IE801386L (en) | 1981-02-02 |
| DE3062741D1 (en) | 1983-05-19 |
| NZ194329A (en) | 1982-05-25 |
| IL60552A (en) | 1984-10-31 |
| ES493926A0 (es) | 1981-04-01 |
| DK152044C (da) | 1988-06-20 |
| FI802384A7 (fi) | 1981-02-03 |
| EP0024560B1 (de) | 1983-04-13 |
| HU181736B (en) | 1983-11-28 |
| EP0024560A1 (de) | 1981-03-11 |
| AU6039080A (en) | 1981-02-05 |
| ATE3038T1 (de) | 1983-04-15 |
| US4279904A (en) | 1981-07-21 |
| ES8104269A1 (es) | 1981-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3420851A (en) | Novel dibenzoxepines | |
| EP0285287A2 (en) | 3-Benzazepine compounds for use in treating gastrointestinal motility disorders | |
| CZ51696A3 (en) | Quinolinecarboxylic acids with carbocyclic and heterocyclic condensed ring and pharmaceutical compositions based thereon | |
| US4731470A (en) | [(5,6-dichloro-3-oxo-2,9a-alkano-2,3,9,9a-tetrahydro-1H-fluoren-7-yl)oxy]alkanoic acids and alkanimidamides | |
| IE51551B1 (en) | Isoquinoline derivatives,process for their preparation and pharmaceutical formulations containing them and their use | |
| KR910005706B1 (ko) | 벤조티아진 유도체의 제조방법 | |
| US5162335A (en) | Di- and tetrahydroisoquinoline derivatives | |
| US4731471A (en) | (5,6-dichloro-3-oxo-2,3,9,9a-tetrahydrofluoren-7-yl)-alkanoic acids and alkanimidamides bearing novel functional 9a-substituents | |
| SU1017170A3 (ru) | Способ получени производных 3-амино-1-бензоксепина или их стереоизомеров, или их солей | |
| NO154495B (no) | Analogifremgangsmaate for fremstilling av en benzopyranforbindelse. | |
| US4132709A (en) | [2]Benzopyrano[4,3-c]pyridine derivatives and process therefor | |
| US4314943A (en) | Heterocyclic substituted aryloxy 3-indolyl-tertiary butylaminopropanols | |
| EP0130555A2 (en) | Dibenz (b,e) oxepin derivatives | |
| US4002632A (en) | Tetracyclic piperidino derivatives | |
| US4835313A (en) | (5,6-dichloro-3-oxo-9α-propyl-2,3,9,9α-tetrahydrofluoren-7-yl) alkanimidamides | |
| IL95167A (en) | History of novel preparation and pharmaceutical preparations containing them | |
| US3941782A (en) | Heterocyclic esters of benzopyrans | |
| US3535315A (en) | Aminoalkyl derivatives of 6,11-dihydrodibenzo-(b,e)-oxepine and -thiepine | |
| US4777281A (en) | [3,4-dichloro-6,7,8,8a,9,10-hexahydro-6-oxo-8a-substituted-2-phenanthrenyl)oxy]-alkanoic acids and -ethanimidamides | |
| US4473586A (en) | Aminoalkyl dihydronaphthalenes | |
| HUT54616A (en) | Process for producing new benzocycloheptene derivatives and pharmaceutical compositions containing them | |
| US3910927A (en) | 3-Hydroxyisoquinoline ethers | |
| US4279905A (en) | 1-Benzoxepin-5 (2H)-one derivatives and pharmaceutical compositions | |
| EP0028485B1 (en) | Spiro-imidazolones for alleviating diabetes-associated conditions, processes for preparing them, and pharmaceutical compositions containing them | |
| US4517365A (en) | Isocarbostyril derivative |